JNJ Stock Overview
Researches, develops, manufactures, and sells various products in the healthcare field worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
Community Narratives
Narratives bring a range of perspectives from our community.
Rich Drug Pipeline Will Push Revenues and Earnings Higher
Industry Tailwinds, Company Headwinds And New Products Will Lead To Stable Revenue Growth
Johnson & Johnson Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$167.38 |
| 52 Week High | US$168.85 |
| 52 Week Low | US$143.13 |
| Beta | 0.52 |
| 11 Month Change | 4.21% |
| 3 Month Change | 15.11% |
| 1 Year Change | 2.32% |
| 33 Year Change | 1.57% |
| 5 Year Change | 29.08% |
| Change since IPO | 26,680.84% |
Recent News & Updates
Why Investors Shouldn't Be Surprised By Johnson & Johnson's (NYSE:JNJ) P/E
Sep 10
We Think Johnson & Johnson (NYSE:JNJ) Can Stay On Top Of Its Debt
Aug 23Johnson & Johnson: Don't Bet Against Double Compounding
Aug 22Recent updates
Why Investors Shouldn't Be Surprised By Johnson & Johnson's (NYSE:JNJ) P/E
Sep 10We Think Johnson & Johnson (NYSE:JNJ) Can Stay On Top Of Its Debt
Aug 23Johnson & Johnson: Don't Bet Against Double Compounding
Aug 22Johnson & Johnson Q2: Robust New Product Pipeline
Jul 17Johnson & Johnson Q2 Earnings Preview: Scrutinizing Its Earnings Quality
Jul 11Johnson & Johnson: A Lot Of Moving Parts, But Perhaps Finally Lurching In The Right Direction
Jul 03There's Reason For Concern Over Johnson & Johnson's (NYSE:JNJ) Price
Jun 10Shareholder Returns
| JNJ | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.1% | -2.7% | -3.4% |
| 1Y | 2.3% | 15.8% | 19.6% |
Return vs Industry: JNJ underperformed the US Pharmaceuticals industry which returned 15.8% over the past year.
Return vs Market: JNJ underperformed the US Market which returned 19.6% over the past year.
Price Volatility
| JNJ volatility | |
|---|---|
| JNJ Average Weekly Movement | 2.4% |
| Pharmaceuticals Industry Average Movement | 10.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: JNJ has not had significant price volatility in the past 3 months.
Volatility Over Time: JNJ's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1886 | 131,900 | Joaquin Duato | www.jnj.com |
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke.
Johnson & Johnson Fundamentals Summary
| JNJ fundamental statistics | |
|---|---|
| Market cap | US$401.07b |
| Earnings (TTM) | US$16.38b |
| Revenue (TTM) | US$86.58b |
24.6x
P/E Ratio4.7x
P/S RatioIs JNJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JNJ income statement (TTM) | |
|---|---|
| Revenue | US$86.58b |
| Cost of Revenue | US$26.47b |
| Gross Profit | US$60.11b |
| Other Expenses | US$43.73b |
| Earnings | US$16.38b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 15, 2024
| Earnings per share (EPS) | 6.81 |
| Gross Margin | 69.43% |
| Net Profit Margin | 18.92% |
| Debt/Equity Ratio | 58.0% |
How did JNJ perform over the long term?
See historical performance and comparison